SensoDetect AB (publ) today announced the launch of a major artificial intelligence and machine learning initiative aimed at enhancing its proprietary diagnostic technology. The project leverages cutting-edge AI models to improve signal processing, identify key biomarkers, and boost diagnostic precision—positioning the company for accelerated growth in the global medtech market.

Running throughout 2025, the initiative will focus on advanced data pre-processing, signal optimization, and the development of AI-driven models in collaboration with leading partners in neuroscience and data science. The goal is to significantly enhance the efficiency and accuracy of SensoDetect’s Brainstem Evoked Response Audiometry (BERA)-based platform, particularly in the early detection of psychiatric and neurological conditions.

"We are very optimistic about this new chapter in SensoDetect’s journey," says CEO PA Hedin. "This project will not only refine our current methods—delivering faster and more accurate results—but also open the door to entirely new diagnostic applications. It represents substantial value creation for both patients and shareholders."

By combining medtech expertise with advanced AI capabilities, SensoDetect is targeting improved scalability and stronger market competitiveness. The company’s innovation-focused strategy is aligned with increasing global demand for precision diagnostics and is expected to drive long-term value in both clinical outcomes and investor returns.